News
Stéphanie Moy
+33 (0)6 32 55 85 48
s.moy@quantumsurgical.com
%20(1)-min.png)

An exciting and busy year 2024 at Quantum Surgical
It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:
- The Paoli-Calmettes Institute in Marseille, France, acquired Epione. About 30 patients have since been treated by Dr Piana and his team.
- Quantum Surgical received €30 million financing from the European Investment Bank.
- Quantum Surgical launched the Epibone clinical study to assess Epione®’s performance to treat bone tumors.
- Rush University System for Health in Chicago (IL) acquired Epione®.
- Dr. Naranayan and his team celebrated the 150th patient treated at Baptist Health, Miami (FL).
- Quantum Surgical received the French National Institute of Industrial Property Award in the Start-up category.
- Quantum Surgical organized a webinar with the Baptist Health IO team.
- Quantum Surgical’s first symposiums took place in USA at Spectrum in Miami and in Europe at ECIO in Mallorca, Spain.
- Quantum Surgical obtained ISO 27001:2023 certification which attests to the security and rigor of its data management system.
- Bertin Nahum, CEO and co-founder, spoke at CES in Las Vegas, the biggest tech event in the world.
- Lucien Blondel, our CTO and co-founder, received the Surgical Robotics Industry Award of Industry Leadership.
- LSI Europe invited Quantum Surgical to present the Epione® solution in Lisbon, Portugal.
- Quantum Surgical and Epione® attended various events worldwide: Spectrum in Miami, FL; ECIO in Mallorca, Spain; CIRSE in Lisbon, Portugal; Medpeers in Amsterdam, The Netherlands…
- And 720+ patients have been treated overall!
We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!


‘I Literally Didn’t Have Any Organs Left to Take Out’: How Epione®, a Minimally Invasive Robotic-Assisted Ablation Technology Transformed a Cancer Patient’s Life
A groundbreaking achievement: Miami Cardiac and Vascular Institute and Miami Cancer Institute, part of Baptist Health South Florida, led the nation as the first to offer Epione, a cutting-edge robotic-assisted technology for minimally invasive ablation procedures. This technology has successfully transformed care for countless cancer patients.
For patients like Jose, the battle against renal cell carcinoma is a marathon, not a sprint. Diagnosed in 2006, Jose underwent a complete nephrectomy, removing his entire left kidney. Last year, his journey took another challenging turn when he developed metastatic lesions in the lower lobe of his right lung and pancreas, requiring additional surgeries. But when a lesion appeared in his remaining kidney, surgery was no longer an option.
Facing this new hurdle, Jose’s team at Miami Cancer Institute turned to innovation. They recommended a minimally invasive procedure using Epione, a robotic-assisted technology for percutaneous ablation. Given the tumor type and its location, the team decided that cryoablation would provide Jose with the best possible outcome.
Dr. Ripal Gandhi, a vascular and interventional radiologist with over 15 years of experience, led Jose’s procedure. A global thought leader in minimally invasive therapies, Dr. Gandhi specializes in cutting-edge treatments for cancer, peripheral vascular disease, and more. His expertise and Epione’s advanced technology offered Jose a new path forward in his ongoing fight against cancer.
“The benefits of the Epione robotic system is it allows us to treat patients more precisely, we are able to access lesions which sometimes would take us hours or sometimes we could not treat at all,” shared Dr. Gandhi. “It allows us to treat patients who may have a lot of issues, who might have a lot of comorbidities, who might not be safely placed under anesthesia for a long period of time, where you can treat the patient much faster and do it safely.”
For Dr. Gandhi and his colleagues at Miami Cancer Institute, Epione has been a ‘game-changing technology’.
“When we are doing procedures robotically versus freehand, these procedures are done much faster. It’s really beneficial for everybody; it’s beneficial for the patient as they are under anesthesia for a shorter period of time, and we are able to do more procedures in the room. Patients can have a faster recovery,” adds Dr. Gandhi.
Thanks to this minimally invasive, cutting-edge procedure, Jose has been given a renewed sense of hope and a cancer-free future. He and his family are deeply grateful to Dr. Gandhi and the team at Miami Cancer Institute for their exceptional care. At his most recent follow-up appointment, Jose was thrilled to share that he remains cancer-free, a testament to the power of innovation and expertise in modern medicine.


Webinar on Robotic- Assisted Ablation for Abdominal Tumors: Expert Perspectives and Case Reviews
Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.
The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.
Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.
Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.